Guselkumab

Medical uses

Guselkumab is indicated to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.

Adverse effects

The most common side effects for guselkumab are upper respiratory tract infections, headache, injection site reactions, joint pain, diarrhea, gastroenteritis, fungal skin infections and herpes simplex infections.

Pharmacology

Mechanism of action

Guselkumab targets the IL-23 subunit alpha (p19 subunit) preventing it from binding to cell receptors that would otherwise be activated by its presence.

Pharmacokinetics

• Cmax 8.09 μg/mL
• tmax 5.5 days
• volume of distribution 13.5 L
• apparent clearance 0.516 L/day

History

Guselkumab was developed by Janssen Pharmaceuticals. In November 2016, Janssen submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking approval of guselkumab.

Society and culture

Legal status

In July 2017, the US Food and Drug Administration (FDA) approved guselkumab for the treatment of plaque psoriasis.

In November 2017, Health Canada approved guselkumab for the treatment of plaque psoriasis. In September 2020, the approval was expanded to include the treatment of adults with psoriatic arthritis.

In April 2018, guselkumab was approved in Japan for the treatment of psoriatic arthritis.

In July 2020, the FDA approved guselkumab as the first IL-23 inhibitor to treat active psoriatic arthritis (PsA).

In September 2024, the FDA approved guselkumab for the treatment of moderately to severely active ulcerative colitis in adults.

In May 2025, the UK Medicines and Healthcare products Regulatory Agency approved guselkumab for Crohn's disease and ulcerative colitis.

Economics

The list price of each 100 mg dose is about .

Names

During development, guselkumab was referred to as CNTO-1959.

Research

Guselkumab has undergone phase III clinical trials comparing it with adalimumab (Humira) and ustekinumab (Stelara).

The safety and efficacy of guselkumab was compared to a placebo and to adalimumab in the "VOYAGE 1" and "VOYAGE 2" phase III clinical trials (ClinicalTrials.gov IDs: NCT02207231 and NCT02207244). Preliminary results indicated that a significantly higher proportion of patients taking guselkumab had better skin clearance compared to those taking the other treatments. At week 16, 73.3% of patients taking guselkumab achieved a PASI 90 (90% reduction in PASI score from baseline), vs 49.7% of those taking adalimumab; additionally, 91.2% of patients taking guselkumab achieved a PASI 75 (75% reduction in PASI score from baseline), vs 73.1% of those taking adalimumab.

The phase III clinical trial "NAVIGATE" (ClinicalTrials.gov ID: NCT02203032) included only patients who had poor responses to treatment with ustekinumab. It showed that patients who switched to guselkumab from ustekinumab did better than those who remained on ustekinumab.

References

References

1. "Tremfya (Guselkumab) Australian Product Information". The Australian Government.
2. (2017-11-27). "Product information".
3. (9 May 2018). "Skin health".
4. (1 November 2020). "Tremfya 100 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)".
5. (10 November 2017). "Tremfya EPAR".
6. (June 2018). "Guselkumab". National Institute of Diabetes and Digestive and Kidney Diseases.
7. "Tremfya- guselkumab injection".
8. (July 2023). "A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections". Journal of Cutaneous Medicine and Surgery.
9. (3 August 2017). "Tremfya". U.S. [[Food and Drug Administration]] (FDA).
10. (November 2000). "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12". Immunity.
11. (14 July 2017). "Janssen Wins FDA Approval for Plaque Psoriasis Treatment Tremfya". Genetic Engineering & Biotechnology News.
12. "Janssen Submits Application to EMA Seeking Approval of Anti-Interleukin-23 Monoclonal Antibody Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis". Janssen.
13. (25 January 2021). "Novel Drug Approvals for 2017". U.S. [[Food and Drug Administration]] (FDA).
14. (2017-11-10). "Regulatory Decision Summary for Tremfya".
15. (2020-09-04). "Regulatory Decision Summary for Tremfya".
16. "MorphoSys' licensee Janssen receives Japanese approval for Tremfya to treat moderate to severe forms of psoriasis & psoriatic arthritis".
17. "FDA approves Tremfya (guselkumab) for psoriatic arthritis".
18. (14 July 2020). "DGAP-News: MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis". Bloomberg.com.
19. "Tremfya (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease". Johnson & Johnson.
20. (16 May 2025). "MHRA approves guselkumab for Crohn's disease and ulcerative colitis".
21. (13 July 2017). "Johnson & Johnson's Tremfya gets its go-ahead to fight Novartis, Lilly in psoriasis. Can it stand out?". Fierce Pharma.
22. (September 2017). "Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials". Dermatology and Therapy.
23. (September 2017). "Guselkumab: First Global Approval". Drugs.
24. Janssen Research & Development, LLC. (2017-08-11). "A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab". clinicaltrials.gov.